

Press release 2012-10-30

## WntResearch: Positive pre-clinical toxicology studies on Foxy-5

**WntResearch AB (WNT.ST) announces positive results from the FOXY-5 four weeks pre-clinical toxicology studies. The conclusion is that FOXY-5 was well tolerated with no unexpected toxicity observed. These data will be part of the Clinical Trial Application to EMA (the European health authorities), which the Company expects to file in order to initiate Phase 1 clinical trial at the end of 2012/beginning of 2013.**

**CEO Nils Brünner comments:**

"These very positive results mean that we can keep our time plan and expect to initiate the clinical phase 1 study end of 2012/beginning of 2013."

**For further information please contact:**

Nils Brünner, CEO  
E-mail: [nbr@wntresearch.com](mailto:nbr@wntresearch.com)  
Telephone: +45 2614 4708

**About WntResearch AB**

*WntResearch (WNT.ST) is a public company listed at the AktieTorget and is a research based Biotech Company spun out of Lund University, Sweden, founded in 2007. The focus and aim of WntResearch is to develop novel anti-metastatic therapies, in areas of unmet need, for the treatment of cancer patients. The company has two major drug development projects, Foxy-5 and Box-5. The lead project Foxy-5 is planned to enter phase 1 clinical trials in metastatic cancer in the end of 2012 / beginning of 2013.*